See more : Plexus Holdings plc (POS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Tau Medical Ltd. (DRTSW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Tau Medical Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Prom Resources, Inc. (PRMO) Income Statement Analysis – Financial Results
- Tirupati Starch and Chemicals Limited (TIRUSTA.BO) Income Statement Analysis – Financial Results
- Bannix Acquisition Corp. (BNIX) Income Statement Analysis – Financial Results
- Evolution Solar Corp (EVSO) Income Statement Analysis – Financial Results
- Olympic Steel, Inc. (ZEUS) Income Statement Analysis – Financial Results
Alpha Tau Medical Ltd. (DRTSW)
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 979.00K | 776.00K | 86.00K | 0.00 |
| Gross Profit | -1.07M | -979.00K | -776.00K | -86.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.42M | 20.89M | 11.45M | 7.54M | 6.64M |
| General & Administrative | 7.33M | 10.27M | 1.86M | 1.41M | 977.00K |
| Selling & Marketing | 1.92M | 974.00K | 482.00K | 288.00K | 397.00K |
| SG&A | 9.26M | 11.25M | 2.34M | 1.70M | 1.37M |
| Other Expenses | -72.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Cost & Expenses | -35.68M | 32.14M | 13.79M | 9.24M | 8.01M |
| Interest Income | 4.76M | 1.79M | 211.00K | 613.00K | 776.00K |
| Interest Expense | 39.00K | 1.77M | 13.27M | 217.00K | 0.00 |
| Depreciation & Amortization | 1.07M | 979.00K | 776.00K | 86.00K | 66.00K |
| EBITDA | -28.03M | -32.74M | -13.22M | -9.16M | -7.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 35.68M | -32.14M | -13.79M | -9.24M | -8.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.82M | -1.61M | -13.47M | 520.00K | -308.00K |
| Income Before Tax | -29.14M | -33.74M | -27.26M | -8.72M | -8.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 16.00K | 20.00K | 7.00K | 158.00K | 146.00K |
| Net Income | -29.16M | -33.76M | -27.27M | -8.88M | -8.46M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| EPS Diluted | -0.42 | -0.53 | -0.67 | -0.22 | -0.13 |
| Weighted Avg Shares Out | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
| Weighted Avg Shares Out (Dil) | 69.38M | 63.53M | 40.53M | 40.43M | 67.62M |
Source: https://incomestatements.info
Category: Stock Reports